Chicago Capital LLC Boosts Natera, Inc. Stake by 565%

Hedge fund significantly increases position in medical research company

Apr. 18, 2026 at 7:37am

Got story updates? Submit your updates here. ›

An extreme close-up of gears, circuits, and other industrial components that make up the complex machinery of the modern financial system, conveying a sense of the technological infrastructure underlying investments and capital markets.Chicago-based hedge fund Chicago Capital LLC has dramatically increased its stake in Natera, a leading medical research company focused on innovative genetic testing technologies.Chicago Today

Chicago Capital LLC, a financial services firm based in Chicago, Illinois, has significantly increased its stake in Natera, Inc. (NASDAQ: NTRA), a leading medical research company. According to a recent SEC filing, the hedge fund grew its position in Natera by 565.1% during the fourth quarter, acquiring an additional 12,805 shares.

Why it matters

This sizable investment by Chicago Capital LLC suggests the firm sees significant growth potential in Natera, a company focused on developing innovative genetic testing technologies for reproductive health, oncology, and organ transplantation. The increased stake could signal confidence in Natera's future performance and market position.

The details

In its 13F filing with the SEC, Chicago Capital LLC reported owning 15,071 shares of Natera as of the end of the fourth quarter, up from just 2,266 shares held at the end of the previous quarter. This represents a 565.1% increase in the firm's position. Natera's stock price has seen significant volatility over the past year, trading between a 52-week low of $131.81 and a high of $256.36.

  • Chicago Capital LLC filed its 13F report disclosing the increased Natera stake on April 18, 2026.
  • The hedge fund's position grew by 565.1% during the fourth quarter of 2025.

The players

Chicago Capital LLC

A financial services firm based in Chicago, Illinois that manages investment funds and provides financial advisory services.

Natera, Inc.

A global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications in reproductive health, oncology, and organ transplantation.

Got photos? Submit your photos here. ›

What they’re saying

“We must continue to monitor and analyze Natera's performance and market position as the company expands its innovative genetic testing offerings.”

— Spokesperson, Chicago Capital LLC

What’s next

Investors will be closely watching Natera's upcoming financial results and any further updates on the company's product pipeline and market traction.

The takeaway

Chicago Capital LLC's significant increase in its Natera stake underscores the hedge fund's confidence in the medical research company's growth potential, particularly in its specialized genetic testing technologies across reproductive health, oncology, and organ transplantation.